Mechanism of Action and Clinical Impact of Ribociclib-Response

Clin Cancer Res. 2017 Sep 15;23(18):5658. doi: 10.1158/1078-0432.CCR-17-1819.

Authors

Debu Tripathy¹, Aditya Bardia², William R Sellers³

Affiliations

¹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. dtripathy@mdanderson.org.
² Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, Massachusetts.
³ The Broad Institute and Dana-Farber Cancer Institute, Cambridge, Massachusetts.

PMID: 28916619
DOI: 10.1158/1078-0432.CCR-17-1819

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Aminopyridines
Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
Humans
Neoplasms*
Purines

Substances

Aminopyridines
Purines
Cyclin-Dependent Kinase 4
ribociclib

Grants and funding